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Circulating IgG from a large subset of bullous pem-
phigoid (BP) patients reacted on immunoblot with a 
120-kDa protein in conditioned keratinocyte culture 
medium and in keratinocyte cell extracts. A protein 
with a similar molecular weight was recognized by 
circulating IgA from a subset of patients with linear 
IgA dermatosis (LAD). Both affinity-purified 120-
kDa-specific BP IgG and 120-kDa-specific LAD IgA 
bound to the roof of salt-split skin. Both proteins 
recognized are collagenous glycoproteins. Deglyco-
sylation with N-glycosidase F resulted in an identical 
reduction in molecular weight for both the BP-IgG-
recognized protein and the LAD-IgA-recognized 
protein. Both proteins were equally susceptible to 
digestion with type VII collagenase. Furthermore, 
both proteins were absent from conditioned culture 
medium of keratinocytes from patients with BP180-
T he history of identifi cation of the bullous pe~plngoid (BP) antigen dates back to 1977 when Dl3Z et a/ (1977) identified a 20-kDa soluble protein from the epidermis of sodium tlnocyan3te-split skin that was able to absorb BP-antibody staining of the epiderm al 
basement membrane zone (EBMZ) as shown by indirect immuno-
fluorescence. Four years later Stanley et (// (1981) described a 
220-kDa protein present in cultured epidermal cells that was 
irnmunoprecipita ted by BP patient serum. It is tins antigen that is 
now known as BP230. In 1986, Labib et (// (1986) described the 
reaction on immunoblot ofBP serum with five different epidernn s-
derived antigens of 240 kDa (BP230), 200 kDa, 180 kDa, 97 kDa, 
and 77 kDa. The molecular heterogeneity of the BP antigens was 
confirmed by Meyer et (// (1 990), who identified bands of 240 kDa 
(BP230), 200 kDa, 160 kDa, and 100 kDa on an immunoblot. By 
affinity-purifying antibodies from western blots, they were able to 
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deficient general atrophic benign epidermolysis bul-
losa (GABEB). Immunodepletion studies showed that 
the 120-kDa LAD antigen could be removed from 
conditioned culture medium by anti-120-kDa BP IgG. 
Thus these results indicate that these proteins are either 
highly related or, most probably, identical. A strong 
antigenic relationship between the 120-kDa protein and 
the 180-kDa bullous pemphigoid antigen (BP180) was 
detected by cross-reaction of affinity-purified anti-120-
kDa BP patient antibodies to BP180 and cross-reaction 
of monoclonal anti-180-kDa antibodies to the 120-kDa 
protein. Notwithstanding this cross-reactivity, the 120-
kDa protein also exhibits unique epitopes demon-
strated by the nonreactivity of individual anti-120-kDa 
BP and LAD patient serum with the 180-kDa antigen. 
K ey words: alttoalltigellltype XVII collagellILAD-1/jllltctiollal 
epidel,.,IIo1ysis bllilosa. ] Invest Demla.tol 108:423-429, 1997 
show that the purified antibodies cross-reacted in two groups, the 
240- to 200-kDa group and tile 160- to 100-kDa group . In 
subsequent work they showed that proteolytic degradation during 
epidermal extract preparation could be responsible for the appear-
ance of the 160- to 100-kDa antigens and that tllese were probably 
breakdown products of the 180-kDa antigen (BP180) (Meyer e/ ai, 
1991) . The existence of two major antigens, BP230 and BP180, is 
now confirmed by many laboratories. Both appear to be compo-
nents of the hemidesmosome (Ishiko et (//, 1993). Isolation of 
cDNAs allowed the assignment of human BPAGl (coding for 
BP230) to clu'omosome 6 and human BPAG2 (coding for BP180) 
to chromosome 10 (Sawamura et (//, 1990; Li e/ (/ /, 1991). The 
potential pathogenicity of antibodies directed against BP230 and 
BP180 h as been underscored in anin131 models . in which the 
presence of these antibodies resulted in a BP-like blistering disease 
(anti-BP180) or in enhanced inflammatory reactions (anti-BP230) 
(Hall e/ (//, 1993; Liu et (/1. 1993). A potential tlnrd antigen was 
described by Gao and BYStryll (1 994). w ho found that some BP 
serum reacted with a 125-kDa protein localized to the dennal side 
of salt-split skin. R ecently, M arinkovich et a/ (1996) found that IgA 
serum from linear IgA dermatosis (LAD) patients recoglnze a 
97/120-kDa protein localized to the epidermal side of salt-split 
skin. 
We now report that a 120-kDa glycosylated collagenous protein 
is immunologically recogtnzed by serum IgG from a large subset of 
BP patients . T ins protein is synthesized by human keratinocytes and 
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is localized to the epidermal side of salt- split skin. In characteriza-
tion experiments, this 120-kDa BP protein behaved indistinguish-
ably from the 120-kDa LAD antigen. 
MATERIALS AND METHODS 
Patient Serum Patients were selected according to clinical history and 
serum immunofluorescence titer [linear EDMZ IgG, DP and epidermolysis 
bullosa aquisita (EDA); linear EDMZ IgA, LAD; "cell surface" IgG. 
pemphigus vulgaris and pemphigus foliaceus; endomysium IgA, dermatitis 
herpetiformis]. DP and EDA patients were immunoblot-spccific for their 
respective antigens (DP, 230 kDa andlor 180 kDa; EDA, 290 kDa). Two 
sera (serum 12 and 50) were included that were initially judged neg"tive in 
indirect immunofluorescence but gave clear 180-kDa staining in immuno-
blots. Tlus is in accordance with the low indirect immunofluorescence titers 
on monkey esophagus displayed by IlP180-specific serum (Pas et ai, 1995). 
Patient 17 was diagnosed clinically and histopathologically as DP, the serum 
was EDMZ IgG indirect immunofluo.rescence-positivc and labeled the roof 
of salt-split skin, but on aJ1 immunoblot did not bind to Dp230 or IlP180. As 
nonautoimmune controls, we used n0n11al human plasma samples routinely 
analyzed by the laboratory for C1-esterase deficiency (samples 29 -32). AIl 
data are compiled in Table I. 
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) Substrates Keratinocyte cell extracts for SOS-PAGE were 
prepared from serum-free cultured cells as described (Pas et aI, 1995). Spent 
cu lture medium was routinely collected and stored at -20°C until used for 
substrate preparation. After thawing, cellular debris and dead cells were 
removed by 0.22-J.Lm (pore-size) filtration . The filtrate was then concen-
trated by ultrafiltration, nlixed with SOS-PAGE sample buffer, and stored at 
-20°C. In addition to normal human keratinocyte substrates, we used 
substrates derived from cultured. keratinocytes prepared from p"tients with 
genodermatoses from 6-mm pt1l1ch biopsies, by the method of Mitra and 
Nickoloff(1994). As donors, we used two unrelated general atrophic benign 
epidermolysis bullosa (GAIlED)-paticnts deficient in BP180 O0l1kJnan el ai, 
1995) and one patient with keratiJ1 14-deficient recessive epidermolysis 
bullosa simplex Oonkman et aI, 1996b). 
Immunoblotting SDS-PAGE and iml11unoblotting werc performed es-
sentially as described (Pas et ai, 1995). AJ1tigenic specificity ofpaticnt serum 
was determined by using the ImlTIunetics Miniblotter 28 system (lmmunet-
ics, Cambridge, MA), and for substrate comparisons, the whole blot was 
incubated with a 1 :300 dilution of the relevant patient serum . AIl immu-
noglobulin binding was developed by using three-step sys tems . IgG was 
developcd by using AffiJUPure mouse anti-human IgG, Fc-fragmcnt-
specific Oackson [nununoResearch Laboratories, West Grove, PA) as a 
second step and blotting-grade affinity-purified goat 311ti-mouse IgG (heavy 
and light chains) alkaline phosphatasc-conjugated (Dio-R"d, Hercules, CAl 
as the third step . For IgA, the second step consisted of Affin.iPure goat 
anti-human scrum IgA, O'-chain-specific Oackson ImmunoResearch), and 
the t1lird step consisted of alkaline phosphatase-conjugated AffiniPure rabbit 
anti-goat IgG, Fc-fragment-specific Oackson ImmuIloResearch). Mouse 
monoclonal antibodies were developed with AffiluPure goat anti-mouse 
IgG, FC1'-fragmellt-specific Oackson ImmunoRescarch) followed by alka-
line phosphatase-conjugated AffiniPure rabbit anti-goat IgG, Fc-fragment-
specific. To establish the correct position of the antigen on thc blot and to 
detect small variations in molecular weight of recognized antigens, we 
developed a calibration procedure bascd on biotill-streptavidin interaction. 
Briefly, the substrate was mixed with biotinylated SOS-PAGE st311dards, 
broad range (Bio-Rad, Hercules, CAl, and SDS-pAGE and iml11unoblotting 
were performed. After visualizing and digit,,1 recording of the immunoglob-
ulin recognition patterns, the blot was reincubatcd in a 1:1000 dilution of 
alkalioe phosphatase-conjugated streptavidin (Oako, Glostrup, Denmark). 
After standard wash ing procedures, the blot was redeveloped, showing the 
biotinylatcd marker proteins as horizontal bands extending over the whole 
blot. Individual lanes could then accurately be compared for recognized 
antigens, because small aberrations in running distance were casi ly noted. 
Monoclonal Antibodies IlP180-specific monoclonal antibodies were 
kindly provided by Dr. K. Owaribe (Nagoya Uluversity . Nagoya, Japan) . 
Monoclonal antibodies 233 and 101 arc specific to the extracellular part of 
BP180 whereas monoclonal antibody 1 A8C is specific to t.he intracellular 
part (Nishizawa et ai, 1993). Rat anti-90-kDa heat shock protein (anti-
I-lSP90) monoclonal antibody, used as a contro l in deglycosylation experi-
ments, was fr0111 StressGen (StressGen, Victoria, Canada) and is specific for 
human HSP90. 
Indirect Immunofluorescence Circulating anti- epidermal basement 
membrane zone antibodies (anti-EMIlZ) were determined by indirect 
immunofluorescence microscopy using monkey esophagus or sa lt-split skin 
as antigenic substrates, as desclibed (de Jong et nl, 1996). The fluorescence 
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Table I. 
Disease" 
DP 
Ill' 
Ill' 
BP 
BP 
BP 
BP 
Ill' 
BP 
Ill' 
DP 
BP 
liP 
BP 
Ill' 
BP 
BP 
EllA 
EDA 
EDA 
EllA 
EBA 
PF 
PV 
PV 
PV 
PV/PF 
PV/pF 
Clcon 
Clcon 
Clcon 
Clcon 
LAD 
LAD 
LAD 
LAD 
LAD 
LAD 
LAD 
OH 
OH 
OH 
BP 
liP 
DP 
liP 
DP 
BP 
lip 
DP 
liP 
Patient Sera Used in This Study 
Age 
(years) 
77 
90 
60 
78 
96 
73 
79 
70 
70 
86 
90 
82 
72 
90 
78 
85 
87 
fl.a. 
38 
78 
l1 .a. 
n.a. 
83 
48 
65 
74 
80 
75 
50 
19 
24 
30 
3 
4 
34 
4 
24 
5 
30 
49 
63 
46 
71 
72 
97 
43 
69 
79 
76 
78 
79 
llF Titer' 
640 
320-640 
160 
> 160 
1280 
> 160 
> 40 
80 
40 
2560 
640 
10 
40 
10 
40 
20-40 
160 
20-40 
40 
320-640 
160 
40 - 80 
1280 
320 
1280-2560 
» 320 
80 
16 
32 
80 
20 
128 
> 40 
16 
128 
40-80 
> 10 
40 
40 
40 
10 
20 - 40 
160 
80 
> 40 
230 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
lmmunoblot.f 
180 
+ 
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+ 
+ 
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+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
290 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
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+ 
o 
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+ 
o 
:t 
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+ 
+ 
.. All oLUllbcrs indicate different p:l ticnts with the cXCC ptiOll of sera 15 and 50. which 
arc from the same patient but collected 'It differcnt occasions. 
/, PV. pcmphigus vulgaris; PF. pcmphigus foliaccus ; DH, dcrmatitis hcpetifonn is; 
PV I PF, unclassified pemphigus; 11.01., not available; +. positive; - , negative; ±, very weak: 
D. not done. 
r lndirect immunofluoresccnce (II F) titcrs represent IgG titers in case of BP. EBA, 
PV, and PF and JgA titcrs in case of .LAD and DH and were determined by using 
monkey esophagus as substrate. 
II All il11l11ul1oblots re present IgG binding in .BP and EBA Olnd IgA ill LAD. 
Immunoblotting was perfonncd as describcd (Pas CI nl. \ 995) with a kcrntinocycc cell 
extract as the source of BP230 and BP180. a dermal skin extract as source of the 
290-kDa collagen VII. and conditioned medium as source of rhe 120-kD;1 procein. 
oveday technique used in the experiments in Fig 7 has been extensivel)" 
described (Ilruins el ai, 1994,19953. 1995b), as has the "mosaic" GABEB 
patient used in this study Oonkman et aI, 1995, 1996a). 
Affinity Purification of Anti-120-kDa Serum Antibodies Affinity 
purification of 311ti- 120-kDa antibodies against protein blots was done a 
described by Zone el al (1990) with minor modifications. BrieRy, condi-
tioned medium proteins were separated by SOS-pAGE and electroblotted to 
Immobilon-P (Millipore, Dedford, MA). Cut vertica l strips were used to 
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Figurc 1. Scrunt from BP and LAD paticnts binds to a 120-kDa protcin prcscnt in conditioncd kcratinocytc culture mcdium. Concentrated 
conditioned serum-frce medium of cul tured normal human keratinocytes was scparated by SOS-PAGE and transferred to n.itroceUulose filters. Serum from 
42 individuals was analyzed for binding capacity to conditioned medium proteins by ill1.munoblot. Lnlles 1-1 7, BP patients; Inll es 18- 22, EBA patients; Inlles 
23-28, pemphigus vu lgaris/pemphigus foliaccus patients; Inlles 29- 32, normal human concrols; Inll es 33-39, LAD patients; Inlles 40-42, dermaritis 
herpetiformis paticnts. The .Iane numbers correspond with the patient numbers described in Table 1. Lnllcs 1-32, developcd for 19G binding; Inlles 33-42, 
developed for 19A bind ing. Data from four diffcrent blots we rc incorporated . Lanes were aligncd usin g the 116-kDa biotinylated marker (after redevelopment 
with streptnvidin-AP) as a ca libration marker (data not shown). 
idcnti fy the 120-kOa area, which was then excised from thc blot. As a 
control, similar-sized strips were cut ill the 200-kOa area (were no binding 
was observed). The strips were incubated with 1 ml of 1:20 diluted patient 
serum in 20 mM Tris(hydroxymethyl)amillomethane hyd rochloride buffer, 
pH 7.5, containing 500 mm NaC I and 0.05% Tween 20 (TIBS) for 2 h at 
room temperature followed by two washes with TTBS. Bound immuno-
globulin was then eluted with 600 /kl of20 mM sodium citrate, pH 3.2, and 
0.01 % ovalbum.iI1, at 4°C and immediately neutrali zed by mixing in 150 /kl 
of 2 M Tris(hydroxymethyl)aminomethane hydrochloride, pH 7.5. After 
overnight dialysis at 4°C aga inst PBS containiJlg 0.01 % Tween 20, the 
antibodies were concentrated by ultrafi ltration and stored at - SO°C until 
used. 
Deglycosylatioll Keratinocyte ce ll extracts were prepared by extracting 
H 20-lysed cell s with 50 mM Tris(hydro)('ymcthyl)aminomethane hydro-
chloride, pH S.O, 0.5% SOS. and 0.35%, 2-ll1crcaptoethanol fo llowed by 
heating at 100°C for 15 min and centrifugation for 20 min at 14,000 X g. 
Next, 75 /kl were mixed with 25 /kl of 7.5'X, NOllidet P-40 and 50 ILl of 
water. T he sample was divided into twO 75-/k1 portions, which were 
incuba ted overnight at 37°C either in the presen ce or absence of 0.75 
unit of N-glycos idase F (Boehringer Mannheim, Mannbeim , Germany). 
Concentrated medium extra ct was degl)'cosylated by the addition of 1 
unit of N-glycosidase-F to 75 /kl of native concentrate fo llowed by 
overni ght 37°C incubation. Controls were incubated without addition of 
th e enzyme. 
Collagcnase Digcstion Concentrated medium extract was mixed with 
CaCl2 and the protease inhibitor Pcf.1b lock SC (Boehringer M:mnheim, 
Mannheim , Germany) to fina l concentrations of S 111M and O.S mM , 
respectively. At t = 0, O.OSS uni t of collagenase type VII (high purity grade, 
Sigma, St. Louis, M 0) was added per 100 /kl and the mixture was incubated 
at 37°C. Mter various times, samples were mixed with SOS-PAGE sample 
buffer. Mixing in 50S-PAGE saulplc buffe r inac tivates coll agenase activity 
(data not shown) ; thus a reliable indication of the amount of residual 
collagen is obtained. Control incubations without co llagenase did not show 
an y breakdown of the 120-kOa pro tein. The absence of nonspecific 
proteases in the collagenase was checked by digestion assays with bovine 
sc rUlll albu111in. 
Immunodcplction Protein A-Sepharose beads (S igma, St. Louis, MO) 
were wetted and blocked in 0.1% ovalbumin in TTBS. T hirty microliters of 
gel were l1li.xed with 300 /kl of patient serum dilutcd 1:10 in TInS for 2 h 
at room temperature. The beads were extensively washed to remove 
unbound protein, and 10 /kl of gel were incubated with 20 /kl of concen-
trated conditioned medium . After 2 h of head-over-head incubation at room 
temperatu re, the beads werc centrifuged at 14.000 X .~. The supernatant was 
carefully removed and prepared for SOS-PAGE ana lys is. 
RESULTS 
Serum IgG of Patients with BP Recognizes a 120-kDa 
Protein in Conditioned Keratinocyte Culture Medium. 
Serum of patients with various blisteri.n g diseases was screen e d by 
i111111unoblot for IgG reaction to antigens present in conditioned 
culture m ediu111 (Fig 1). Of 17 BP patients screened, 11 reacted 
with a 120-leDa protein. T his protein w as a produc t of cuJtured 
keratinocytes, because fres h m edium did not contain the protein 
(data not shown) . Before this e xperiment, the se sera had been 
divided into groups based on recognition of the known BP antigens 
of 230 leDa and 180 leDa. All five sera that reacted solely to BP230 
did not bi.nd to the 120-kDa protein (Fig 1, Innes 1- 5) . Of the si.." 
se ra with combined P230 / BP180 staining, five reacted with the 
120- leDa protein (Fig 1 , Inlles 6-11). The five sera that recognized 
sole ly BP180 recognized the 120-leDa protein (Fig 1, Innes 12-16). 
Serum 17, which reacted neith er with BP230 nor with BP180, 
clearl y stained the 1 20- leDa protein (Fig 1 , lnll e 17). Serum from 
e pide rmolysis bullosa aquisita or pemphigus patients and normal 
hllman controls did not bind the 120-leDa protein (Fig 1, tnlles 
18-32). Some of these sera did show a w eak reac tion in the 
120-leDa area on immunoblots, but we show b e low that these weak: 
b ands re present proteins different from the 120-leDa protein recog-
nized by BP serum . The same substrate was screened with seven 
sera of patients with LAD (Fig 1 , lones 33-39) . IgA of six sera 
b o und a 120-leDa protein , these serums aU labeled the roof of 
salt-split skin . The seventh serum labeled the base of salt- split skin 
and, in a dermal extract immunoblot, bound the 290-leDa coUagen 
VII. Three dermatitis h e rpetiformis control sera did not bind the 
120-kDa protei.n (Fig 1, Inll e.~ 40-42). 
BP Serum Binds to a 120-kDa Protein in Keratinocyte Cell 
Extracts Figure 2 shows that the 120-kDa protein is also present 
in keratinocyte ceU extract. For good stainin g of the protei.n , cell 
extracts were con centrate d 2- to 4-fold by ultra filtration. Most sera 
bound to both BP180 and th e 120-leDa protei.n . When the staining 
inte nsi ty ratios of both proteins were compared, the y varied 
between the diffe re nt se ra from excl u siv e ly t h e 120-kDa protein 
to almost excl u sive ly the 180-kDa protein (Fig 2, compare Inll cs 
17 nnd 49). LAD seru m a lso recognize d the 120-kDa prote in in 
these substrates but did not bind BP180 (data not shown) . 
Both 120-kDa Affinity-Purified LAD IgA and BP IgG Bind 
the Roof of Salt-Split Skin To ascertain that the il11munoblot 
recognize d polypeptides localized in til e EBMZ, 120-kDa-specific 
LAD and BP patient antibodies w e re affinity-pmified fi'om western 
b lots and re applied to salt- sp lit skin. Indirect immunofluorescen ce 
showe d that both LAD IgA and BP IgG bound the roof of the split 
skin (Fig 3a,II) . 
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Figure 2. BP serum binds to a 120-kDa protein in keratinocyte cell 
extracts. Concentrated keratinocyte cell extract was separated by SDS-
PAGE, transferred to a nitrocellulose futer, and incubated with serum from 
12 BP patients. The sera were selected based on recognizing BP180 andlor 
the 120-kDa conditioned-medium protein. The numbers under the lanes 
refer to the patient numbers from Table I. The blot was developed for IgG 
binding. Most of the BP1S0-positive sera also recognize the 120-kDa protein. 
The staining intensity ratios of the two bands range between exclusively the 
120-kDa protein (serum 17) and almost exclusively BP180 (serum 49). 
Deglycosylation Results in an Similar Reduction in Molec-
ular Mass for Both the BP-IgG- and LAD-IgA-Recognized 
120-kDa Proteins When keratinocyte cell extract was subjected 
to incubation with N-glycosidase F, which removes protein-bound 
asparagine-linked N-glycans, both BP1 80 and the 120-kDa protein, 
but not BP230, responded by a decrease in molecular mass (Fig 4, 
lal/.es a-c). According to the internal biotinylated ca libration mark-
ers, the decrease in molecular mass for both proteins was es timated 
to be approximately 5 kDa. The same decrease in molecular mass 
was observed for the 120-kDa protein in conditioned medium. The 
120-kDa band recognized by both the BP IgG and the LAD IgA 
moved from just above to just below the 116-kDa biotinyla ted 
marker line (Fig 4, lal/.es e-h) . In contras t, the weak bands in the 
120-kDa area o bserved with EBA serum 18 and pemphigus serum 
26 in Fig 1 were not a.ffected by deglycosylation (Fig 4, lalles j,k). 
Also, their molecular mass is slightly lower (compare with Fig 4, 
fall e i); thus, these bands do not reflect the same protein recognized 
by BP and LAD patient serum. 
BP IgG and LAD IgA Bind to Collagenous Proteins Both 
the BP IgG and the LAD IgA signal appeared equally susceptible to 
collagenase digestion. After addition of collagenase to native 
Figure 3. Immunofluorescence of salt-split skin with affinity-
purified anti-120-kDa BP-IgG and LAD-IgA autoantibodies. Serum 
from LAD and BP patients was affinity-purified agai.nst the nitrocellulose-
bound 120-kDa prote in as described in Materials ami Methods. The eluted 
fractions were applied to salt-spHt skin , and immunoAuorescence showed 
that both LAD anti-120-kDa IgA (a) and BP anti-1 20-kDa IgG (b) labeled 
the roof of the spHt skin. Elutions from control strips excised from above the 
120-kDa band (see Materials alld Methods) did not stain (data not shown). 
Serum used for preparing affinity-purified preparations was from BP-patient 
14 and LAD-patient 35 (Table I) . 
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medium substrate, the digestion of the 120-kDa protein was 
followed by immunoblotting. The amount of intact protein de-
creased with time, and in 30 min all 120-kDa protein was degraded 
(Fig Sa , LAD-IgA-recognized antigen; b, BP-IgG-recognized 
antigen). 
BP180-Deficient GABEB Patients Do Not Express the 120-
kDa Protein Recognized by BP and LAD Serum Keratino-
cytes cultured from BPl80-deficient GABEB patients do not 
e-xpress the 180-kDa antigen (Jonkman et ai, 1995) . When 
conditioned medium of these cells was screened with BP serum 
(Fig 6a, lalles 2,4) or LAD serum (Fig 6b, lalles 2, 4) , the 120-kDa 
protein was absent in both cases. In patient skin the same deficiency 
could be demonstrated. In Fig 7 "mosaic" GABEB skin, in which 
BP180 is present in interrupted segments of about 10 adjacent basal 
cells (Jonkman et ai, 1996a), has been double-stained for BP180 and 
the 120-kDa protein. N either the 120-kDa protein recognized by 
BP IgG (Fig 7a) nor that recognized by LAD IgA (Fig 7d) was 
expressed in the BP180-negative stretches (Fig 7b,e). 
BP 120-kDa-Specific IgG Depletes the 120-kDa LAD Anti-
gen from Conditioned Medium Substrate Since all experi-
ments showed equivalent behavior of the IgG- and IgA-recognized 
protein, we investigated whether BP IgG could bind to the same 
protein recognized by LAD IgA. IgG from sLx patients (four BP, 
one EBA, and one pemphigus patients) was coupled to protein-A 
Sepharose beads. The beads were incubated with native medium 
substra te for 2 h, and after removal of the beads, the remaining 
substrate was analyzed for the 120-kDa LAD antigen. As exp ected, 
EBA and pemphigus vulgaris patient IgG did not remove the 
120-kDa signal (Fig 8, tall es 1,6) . Of the four BP patient serums, the 
two serums that recognized the 120-kDa protein on immll11oblots 
depleted the LAD antigen from conditioned medium (Fig 8, IlIIIes 
4,5) . In contrast, BP serum that stained BP180 and lor BP230 bur 
not the 120-kDa protein on immunoblots did not deplete the LAD 
antigen (Fig 8 , IlIlI es 2,3). 
The 120-kDa Protein and BP180 Contain Cross-Reactive 
Epitopes When affinity-purified LAD IgA a.nd BP IgG were 
reblotted against conditioned m edium substrate, both rebound to 
the 120-kDa protein (Fig 9a,c). When tested with cell extract, 
however, anti-120-kDa BP IgG also bound to BP180, whereas 
anti-120-kDa LAD IgA did not recognize the l80-kDa antigen (Fig 
9b,d) . Thus, BP IgG demonstrates the existence of cross-reactive 
epitopes between BP180 and the l20-kDa protein . N ext we tested 
three BP180-specific monoclonal antibodies. The l20-kDa protein 
was recognized by monoclonal antibodies 233 and 1D1, which are 
directed to the external part of BP180, but not by monoclonal 
antibody lA8C, which is specific for tbe intracellular domain of 
BP180 (Fig 9 , lalles e-J). 
DISCUSSION 
In the experin1ents described herein, we show that BP serum 
recognizes a 120-kDa protein in conditioned keratinocyte culture 
medium and in keratinocyte cell extracts. The protein contains 
carbohydrate side chains and is at least partly collagenous. Its 
presence in the medium suggests that it is a secretion product of 
cultured keratinocytes. Since cell extracts contain the protein in a 
concentration that cannot be explained by residual medium con-
tamination, it is probably either a peripheral membrane protein or 
a protein that binds to the coating of the culture flasks. The 
l20-kDa protein is localized to the roof of salt-split skin, which 
clearly differentiates it from the 125-kDa antigen described by Gao 
and Bystryn (1994) that localized to the dermal side of salt-split 
skin . The 120-kDa protein is recognized independently of the other 
BP antigens, BP230 and BP180. Although the 'majority of the 
120-kDa- specific patients also recogn.ized BP180 and "ice versa, 
some patients reacted solely to the 120-kDa protein or to BP180. In 
agreement with the studies of M arinkovich e/ al (1996), serum IgA 
from LAD patients also bound a 120-kDa protein . SDS-PAGE did 
not show a difference between the molecular masses of the IgG-
and IgA-recognized proteins. 
Figure 4. Deglycosylation of BP180 and the 120-kDa protein. Deglycosylated substrates for immunoblotting were prepared by N-glycosidase F 
treatment as described in N[aterial, ami Metflod,. After SDS-PAGE and transfer to· nitrocellulose, the filters were incubated with serum from various patients 
to study the effect of deglycosylation on the BP and LAD antigens. +, Deglycosylated substrate; -, control substrate incubated in the absence of 
N-glycosidase F. After visualizing the immunoglobulin billding patterns (IgG, lalles a-c,eJJ,k; IgA. lalles g-'), the blots were redeveloped for biotinylated 
markers using streptavidin-AP (sec }Haterials alld Met/rods). Deglycosylation ofkcratinocyte cell extract resulted in a decrease in molecular mass ofBP180 and 
the 120-kDa protein whereas BP230 was not affected (Ialles a-c, note the relative positions of the antigens to the biotinylated markers). The internal control 
HSP90 was not affected by deglycosylation as expected (lalle d). A similar decrease in molecular mass after deglycosylation was observed for the 120-kDa 
protein ill conditioned-medium substrate, both with BP IgG (Iall es eJ) and LAD IgA (falles g, /', i). [n contrast, the weak signal in the same area as the 120-kDa 
protein observed with EllA serum 18 and pemphigus serum 26 (see Fig 1) was not affected by deglycosylation (fall es j,k). The numbers below the lanes 
correspond to the patient numbers described in Table I. Indicated molecular masses are for biotinylated markers on the right and antigens on the left. 
At tlus stage we were faced with two proteins that could very 
well be the same or only share identical molecular masses in 
SDS-PAGE. During subsequent protein characterization experi-
ments, however, both proteins remained completely indistinguish-
able. Both are glycoproteins ""ith a comparable amount of aspar-
agine-linked oligosaccharides. Both proteins are at least partly 
collagenous and are equally susceptible to collagenase. Both pro-
teins localize to the roof of salt-split skin, wluch for the LAD-IgA-
recognized 120-kDa protein agrees with the studies of Marinkovich 
e/ al (1996) and with the ultrastructural localization of the LAD 
autoantigen as studied by immunoelectron microscopy (Haftek et. 
ai, 1994; rsluko et ai, 1996). Both proteins were absent from 
conditioned medium ofBP180-deficient GABEB keratinocytes and 
from GABEB skin. In addition to indicating a possible relationship 
between BP180 and the 120-kDa protein, these experiments 
suggested that the autoimmune IgA and IgG responses could well 
be restricted to only one 120-kDa protein. Tlus idea of a mutual 
antigen was supported by the depletion experiments, which showed 
that BP IgG removes the LAD antigen from medium. Considering 
all tlus evidence, we conclude that it is lughly probable that subsets 
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of both BP and LAD patients respond to the same antigen but by 
different immunoglobulin classes. 
We identified three classes of epitopes by immulloblotttng: 
epitopes restricted to BP180, epitopes restricted to the 120-kDa 
protein, and epitopes cross-reactive between BP180 and the 120-
kDa protein. The results with BP180-specific monoclonal antibod-
ies indicated that tlus antigenic cross-reactivity should be found in 
the extracellular part ofBP180 rather than in the cytoplasnuc part. 
More similal;ties between the extracellular part of BP180 and tile 
120-kDa protein exist. Both are of approximately the same length, 
and both have collagenous domains (Giudice et ai, 1992; Hopkinson 
e/ ai, 1992; Nishizawa et ai, 1993; this study). Furtllermore, all 
BP180 carbohydrate side ch ains are extracellular (Nisluzawa et ai, 
1993) and, according to the deglycosylation experiments in tlus 
study, the amount of N-glycans is comparable with tllat of the 
120-kDa protein. In particular, the absence of the LAD antigen 
from BP180-negative GABEB skin indicates the close connection 
between BP180 and this protein. Three major explanations nught 
be given. (i) The 120-kDa protein might be tile proteolytically 
cleaved extracellular part of BP180. This i" lIillo cleaving process 
. , 
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Figure 5. Collagenase digestion of 
the 120-kDa protein. Conditioned-me-
dium substrate was incubated with coUage-
nase as indicated Materials a .. d Met/rods. 
Samples were taken at the times indicated 
below the lanes (in minutes) and processed 
for SDS-PAGE. After electrophoresis alld 
transfer to nitroceUulose, the fi lters were 
incubated with a mixture of LAD serum (a) 
or BP serum (b) and developed for IgA (a) 
or IgG binding (b). After 30 min of incu-
bation with collagenase, the 120-kDa sig-
nal had disappeared. In blot a, a nUnor 
IgA-recognized protein is visible (indicated 
by the arrow) that was not affected by 
collagenase, indicating the specificity of the 
reaction. In blot I" a small band of lower 
molecular mass also disappeared during 
digestion. A possible short-lived intermedi-
ate was present at 5 and 10 min of digestion 
time (see arrow). The total protein pattem 
did not show any nonspecific proteolytic 
degradation (e). Biotinylated molecular 
mass markers are indicated by M . 
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Figure 6. lmmunoblot of conditioned medium of cultured BP180-
deficient GAllEB keratinocytes. Conditio ncd mcdium obtained fro m 
cultured keratinocytes of fou r different donors were compared by immu-
nob lot for presence of the 120-kDa protein. After electrophoresis and 
transfer to nitrocellulose, the filters were incubated with BP-patient serum 
(n) or LAD-patien t serulll (/J) and deve loped for IgG or IgA binding 
respectively. Medium was ob tained frol11 the following kerati nocytes: Inlle 1, 
normal human ; /tlll e 2, BPISO-deficient GADEB (patient 1); Inlle 3, keratin 
14-deficient recessive epidermolysis bu llosa simplex (keratin 14-negative, 
BP'I 80-pos itive) ; Inlle 4, BP1 S0-deficient GABEB (patient 2). T he medium 
of both GADEB patients was devoid of the 120-kJJa protein recognized by 
BP IgG and LAD IgA. The additiona l lower m olecular mass band observed 
in Inlle 3 of (n) was also observed sometimes in other (healthy) keratinocyte 
medium substrates and probably reAects a degradation product. Serul11 used 
for incubation in (n) was from BP-patient 50 and in (b) was £i'om 
LAD-patient 35 (Table I). 
might then generate new epitopes accounting for the recogni tion of 
unique 120 kOa epitopes by patient antibodies. (ii) T he 120-kOa 
prote in may be a product of alternative splicing of the gene for 
BP180 (COLl7A1) . (iii) Both proteins may derive from different 
genes but share epitopes and may be co-regulated in expression. 
Definite proof for any of these ass umptions is, however, lacking. 
T H E JOUIWAL OF INVESTIGATIVE DE~ATOLOGY 
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Fi g ure S. BP anti-120-kDa IgG depletes the LAD antigen from 
conditioned Itlediunl. Condi tioned medium was incubated with protein 
A-Sepharose beads to which patient IgG was coupled (see Materin ls nlld 
Me/flods). After removal of the beads, the re maining medium was analyzed 
by immunoblotting for the presence of the 120-kDa LAD antigen (n). The 
lan es show the remaining substrate afte r incuba tion w ith beads to which 
IgGs from the following serums were coupled: Inlle 1, pemphigus serum 
(patient 24); Inlle 2, anti-230-kOa- specific BP serum (patien t 1) ; Inlle 3, 
anti-230/1S0-kDa- specific BP serllm (patient 7); Inlle 4, anti-1 S0/120-kDa-
specific DP se rum (patient 50); Inlle 5, anti-1 20-kDa- specific BP scrum 
(patient 17); Inlle 6, anti-collagcn VlI EBA serum (patient 20). Blot a was 
developed for IgA binding after incuba tio n with 120-kDa- specific LAD 
patient serum (patient 35). T he LAD antigen is rcmoved from the substrate 
by IgG from thosc BP sera, which recognize the 120-kDa protein on 
immunoblot, bu t no t by those BP sera, which recognize onl y BP1 S0 andl or 
£1'230 (compare Inlles 2 and 3 to Inll es 4 and 5). T he same pattern of 
depletion was observed if the same substrates were analyzed for the 
120-kDa protein with BP IgG instead of LAD IgA (b, afte r incubation with 
serum from BP-patient 14) . 
Initially the LAD autoantigen was reported to be a 97-kDa 
protein in Skill extract (Zone et ai, 1990). In addition BP serum has 
been reported to recognize a 97-kDa protein in epidermal prepa-
rations (Labib e/ ai, 1986). In line with our own observations for the 
120-kOa protein recognized by BP serum, this epidermal protein 
was recognized independently from BP180. The 97-kDa epidermal 
LAD autoantigen is probably a processed form of the 120-kDa 
F igure 7. BP180-deficient GAllEB skin is devoid of the 120-kDa protein. The skin of a m osa ic GAUED pa tient with DP1S0 present in stretch 
interrupted by DP1S0-nega tive stretches was double-sta iJled for the 120-kDa protein (green Auorescence) and DP180 (red Auorescence). The 120-kDa 
protein was stained by IgG fro m serum of BP-patient 17 , which uniquely recognizes this protein (n), and b), affi ni ty-puri fied anti-1 20-kJJa LAD IgA (d). 
BP180 was stained by anti-B P1 S0 monoclonal antibody 101 (b,e) . After overlay both images combine to give a yellow signal , showing that both BP1S0 and 
the 120-kOa protein arc absent from the negative stretches (cJ) . Scnle bnr, 10 J.Lm. 
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Figure 9. The 120 kDa protein and BP180 contain cross-reactive 
epitopes. Affinity-purified anti-120-kDa LAD IgA and affinity-purified 
anti-120-kDa DP IgG (see Fig 3) were reapplied to western blots to test 
their binding specificity. Anti-120-kDa LAD IgA bound the 120-kDa 
protein in conditioned medium (Iall e a) and in cell extract (lall e b) . 
Anti-1 20-kDa DP IgG also recognized the 120-kDa protein in both 
substrates (lalles c,d) but in addition bound to DP1S0 in the cell extract (Iall c 
d). The 120-kDa protein was also recognized by two of three anti-BPI SO 
monoclonal antibodies, both in conditioned medium (/allcs e-g) and in cell 
extracts (Ialles h-j): lallcs e,h, monoclonal antibody 1 ASC; lallcs j,i. mono-
clonal antibody 233; lall cs gJ, monoclonal antibody 1 Dl . DP serum 14 and 
LAD serum 35 were used for production of affinity-purified antibodies. 
medium protein, because both proteins are recognized by the same 
LAD serum and a 120-kDa-specific monoclonal antibody (Mari.nk-
ovich et aI, 1996) . Tlus processing is probably nonspecific, because 
extraction in the presence of lugh concentrations of protease 
inhibitors resulted in the appearance of the 120-kDa protein in skin 
extracts (Marinkovich et ai, 1996). T herefore, it is to be expected 
that depending on the proper use of protease inhibitors, the 
120-kDa protein recognized by BP serum will also appear in 
epidermal extracts as either a 97-kDa or 120-kDa band . 
We have described the existence of a 120-kDa keratinocyte 
protein that can be recognized independently from BP180 by BP 
patient serum. Furthermore, we provide evidence that this mole-
cule is sinillar to the 120-kDa molecule recogluzed by LAD patient 
serum. For classi.fication of LAD based on immunoblotting, tlus 
would result in a two major subclasses, the a.nti-collagen VII type, 
i.e., IgA-mediated epidermolysis bullosa aquisita (Zambruno et aI , 
1994), and the anti-120-kDa classical LAD type, which shares its 
target a.ntigen with a subset of BP patients. 
NOTE ADDED IN PROOF 
Recently, the mutation in the mosaic GAllED patient used in Figure 7 has 
been revealed. T lus patient appeared to be compound heterozygote with 
cwo nonsense mutations in the gene for DPIS0 (C0L17Al : R1226X/ 
1706delA). The mosaic phenotype was caused by gene conversion of the 
maternal mutation 1706delA, thus repairing the expression of both BPI80 
and LAD-I Oonkman MF, Scheffer H, Stulp RP, Pas HI-I, Nijenhuis M, 
Heeres K, Owaribe K, Pulkkinen L, Uitto J: Kevertant mosaicism in 
epidermolysis bullosa caused by nutotic gene conversion, Cell in press, 
1997. 
We Ihallk Dr. Dick M. Boor"",a and Dr. Cres Niehoerfor sl/pplyil/g senl/I/ sa",ples 
33 and 39 nIId Siep Noor",all alltl Peler VnII der Sijde}'r expe/1 assislance ",ilh color 
figllres. 
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